SMARCB1 and epithelioid sarcoma: Based on the results of a nonrandomized Phase II study (EZH-202; ClinicalTrials.gov: NCT02601950) that included INI1 negative advanced ES, the US FDA granted accelerated approval for tazemetostat (Tazverik R; Epizyme, Inc., 400 Technology Square, MA, USA) for the treatment of adult advanced ES in January 2020.